Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1323 entries
Sorted by: Best Match Show Resources per page
Giant lipoma of the adrenal gland: a case report.

Journal of medical case reports

Patel RD, Vanikar AV, Modi PR.
PMID: 21349167
J Med Case Rep. 2011 Feb 24;5:78. doi: 10.1186/1752-1947-5-78.

INTRODUCTION: Lipoma of the adrenal gland is rare with a reported incidence of between 2% to 4%. Improved imaging techniques have helped in the diagnosis of these lesions.CASE PRESENTATION: We report an incidentally detected giant adrenal lipoma in a...

Cite
Patel RD, Vanikar AV, Modi PR. Giant lipoma of the adrenal gland: a case report. J Med Case Rep. 2011;5:78doi: 10.1186/1752-1947-5-78.
Patel, R. D., Vanikar, A. V., & Modi, P. R. (2011). Giant lipoma of the adrenal gland: a case report. Journal of medical case reports, 578. https://doi.org/10.1186/1752-1947-5-78
Patel, Rashmi D, et al. "Giant lipoma of the adrenal gland: a case report." Journal of medical case reports vol. 5 (2011): 78. doi: https://doi.org/10.1186/1752-1947-5-78
Patel RD, Vanikar AV, Modi PR. Giant lipoma of the adrenal gland: a case report. J Med Case Rep. 2011 Feb 24;5:78. doi: 10.1186/1752-1947-5-78. PMID: 21349167; PMCID: PMC3224449.
Copy Download .nbib Format: NLM
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Oncoimmunology

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.
PMID: 26942070
Oncoimmunology. 2015 Jun 05;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016.

Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated through the IgG Fc receptor FcγRIIIa represents a major effector function of many therapeutic antibodies. In an attempt to further enhance natural killer (NK) cell-mediated ADCC, we combined therapeutic antibodies against CD20 and CD38...

Cite
Kellner C, Günther A, Humpe A, et al. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015;5(1):e1058459doi: 10.1080/2162402X.2015.1058459.
Kellner, C., Günther, A., Humpe, A., Repp, R., Klausz, K., Derer, S., Valerius, T., Ritgen, M., Brüggemann, M., van de Winkel, J. G., Parren, P. W., Kneba, M., Gramatzki, M., & Peipp, M. (2016). Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology, 5(1), e1058459. https://doi.org/10.1080/2162402X.2015.1058459
Kellner, Christian, et al. "Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30." Oncoimmunology vol. 5,1 (2016): e1058459. doi: https://doi.org/10.1080/2162402X.2015.1058459
Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015 Jun 05;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016. PMID: 26942070; PMCID: PMC4760288.
Copy Download .nbib Format: NLM
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma.

Journal of clinical and diagnostic research : JCDR

Vasudevan G, Bishnu A, Singh BMK, Nayak DM, Jain P.
PMID: 28511402
J Clin Diagn Res. 2017 Mar;11(3):ER01-ER04. doi: 10.7860/JCDR/2017/24590.9536. Epub 2017 Mar 01.

Primary urinary Bladder Adenocarcinoma (PBA) is an uncommon neoplasm and can cause diagnostic difficulties due to histologic similarities with adenocarcinomas of adjacent structures like Gastrointestinal Tract (GIT) and prostate, since involvement of the bladder by metastasis or direct spread...

Cite
Vasudevan G, Bishnu A, Singh BMK, et al. Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. J Clin Diagn Res. 2017;11(3):ER01-ER04doi: 10.7860/JCDR/2017/24590.9536.
Vasudevan, G., Bishnu, A., Singh, B. M. K., Nayak, D. M., & Jain, P. (2017). Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. Journal of clinical and diagnostic research : JCDR, 11(3), ER01-ER04. https://doi.org/10.7860/JCDR/2017/24590.9536
Vasudevan, Geetha, et al. "Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma." Journal of clinical and diagnostic research : JCDR vol. 11,3 (2017): ER01-ER04. doi: https://doi.org/10.7860/JCDR/2017/24590.9536
Vasudevan G, Bishnu A, Singh BMK, Nayak DM, Jain P. Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. J Clin Diagn Res. 2017 Mar;11(3):ER01-ER04. doi: 10.7860/JCDR/2017/24590.9536. Epub 2017 Mar 01. PMID: 28511402; PMCID: PMC5427328.
Copy Download .nbib Format: NLM
Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.

Advances in therapy

Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei E, Borghi C.
PMID: 28452039
Adv Ther. 2017 Jun;34(6):1498-1499. doi: 10.1007/s12325-017-0537-4.

No abstract available.

Cite
Omboni S, Malacco E, Napoli C, et al. Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies. Adv Ther. 2017;34(6):1498-1499doi: 10.1007/s12325-017-0537-4.
Omboni, S., Malacco, E., Napoli, C., Modesti, P. A., Manolis, A., Parati, G., Agabiti-Rosei, E., & Borghi, C. (2017). Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies. Advances in therapy, 34(6), 1498-1499. https://doi.org/10.1007/s12325-017-0537-4
Omboni, Stefano, et al. "Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies." Advances in therapy vol. 34,6 (2017): 1498-1499. doi: https://doi.org/10.1007/s12325-017-0537-4
Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei E, Borghi C. Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies. Adv Ther. 2017 Jun;34(6):1498-1499. doi: 10.1007/s12325-017-0537-4. PMID: 28452039; PMCID: PMC5487858.
Copy Download .nbib Format: NLM
The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Gehrie EA, Tormey CA.
PMID: 25670929
Transfus Med Hemother. 2014 Nov;41(6):420-9. doi: 10.1159/000369109. Epub 2014 Nov 17.

In the context of transfusion medicine, alloimmunization most often refers to the development of antibodies to non-ABO red blood cell (RBC) antigens following pregnancy, transfusion, or transplantation. The development of RBC alloantibodies can have important clinical consequences, particularly in...

Cite
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfus Med Hemother. 2014;41(6):420-9doi: 10.1159/000369109.
Gehrie, E. A., & Tormey, C. A. (2014). The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 41(6), 420-9. https://doi.org/10.1159/000369109
Gehrie, Eric A, and Tormey, Christopher A. "The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 41,6 (2014): 420-9. doi: https://doi.org/10.1159/000369109
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfus Med Hemother. 2014 Nov;41(6):420-9. doi: 10.1159/000369109. Epub 2014 Nov 17. PMID: 25670929; PMCID: PMC4280450.
Copy Download .nbib Format: NLM
Acute Kidney Injury and Quadriparesis Due to Rosuvastatin Induced Rhabdomyolysis- A Case Report.

Journal of clinical and diagnostic research : JCDR

Suthar KS, Vanikar AV, Trivedi HL.
PMID: 26155510
J Clin Diagn Res. 2015 May;9(5):OD08-9. doi: 10.7860/JCDR/2015/12117.5909. Epub 2015 May 01.

Statins as lipid lowering drugs, are safe and effective in reducing cardiovascular disease risk, but rarely produce myopathy like myalgia, myositis or rhabdomyolysis. We report the case of Rosuvastatin induced rhabdomyolytic acute renal failure and quadriparesis in a 67-year...

Cite
Suthar KS, Vanikar AV, Trivedi HL. Acute Kidney Injury and Quadriparesis Due to Rosuvastatin Induced Rhabdomyolysis- A Case Report. J Clin Diagn Res. 2015;9(5):OD08-9doi: 10.7860/JCDR/2015/12117.5909.
Suthar, K. S., Vanikar, A. V., & Trivedi, H. L. (2015). Acute Kidney Injury and Quadriparesis Due to Rosuvastatin Induced Rhabdomyolysis- A Case Report. Journal of clinical and diagnostic research : JCDR, 9(5), OD08-9. https://doi.org/10.7860/JCDR/2015/12117.5909
Suthar, Kamlesh S, et al. "Acute Kidney Injury and Quadriparesis Due to Rosuvastatin Induced Rhabdomyolysis- A Case Report." Journal of clinical and diagnostic research : JCDR vol. 9,5 (2015): OD08-9. doi: https://doi.org/10.7860/JCDR/2015/12117.5909
Suthar KS, Vanikar AV, Trivedi HL. Acute Kidney Injury and Quadriparesis Due to Rosuvastatin Induced Rhabdomyolysis- A Case Report. J Clin Diagn Res. 2015 May;9(5):OD08-9. doi: 10.7860/JCDR/2015/12117.5909. Epub 2015 May 01. PMID: 26155510; PMCID: PMC4484102.
Copy Download .nbib Format: NLM
Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control.

International journal of stem cells

De Pascale MR, Bruzzese G, Crimi E, Grimaldi V, Liguori A, Brongo S, Barbieri M, Picascia A, Schiano C, Sommese L, Ferrara N, Paolisso G, Napoli C.
PMID: 27426095
Int J Stem Cells. 2016 May 30;9(1):137-44. doi: 10.15283/ijsc.2016.9.1.137.

BACKGROUND: Circulating endothelial progenitors cells (EPCs) play a critical role in neovascularization and endothelial repair. There is a growing evidence that hyperglycemia related to Diabetes Mellitus (DM) decreases EPC number and function so promoting vascular complications.AIM OF THE STUDY:...

Cite
De Pascale MR, Bruzzese G, Crimi E, et al. Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control. Int J Stem Cells. 2016;9(1):137-44doi: 10.15283/ijsc.2016.9.1.137.
De Pascale, M. R., Bruzzese, G., Crimi, E., Grimaldi, V., Liguori, A., Brongo, S., Barbieri, M., Picascia, A., Schiano, C., Sommese, L., Ferrara, N., Paolisso, G., & Napoli, C. (2016). Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control. International journal of stem cells, 9(1), 137-44. https://doi.org/10.15283/ijsc.2016.9.1.137
De Pascale, Maria Rosaria, et al. "Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control." International journal of stem cells vol. 9,1 (2016): 137-44. doi: https://doi.org/10.15283/ijsc.2016.9.1.137
De Pascale MR, Bruzzese G, Crimi E, Grimaldi V, Liguori A, Brongo S, Barbieri M, Picascia A, Schiano C, Sommese L, Ferrara N, Paolisso G, Napoli C. Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control. Int J Stem Cells. 2016 May 30;9(1):137-44. doi: 10.15283/ijsc.2016.9.1.137. PMID: 27426095; PMCID: PMC4961113.
Copy Download .nbib Format: NLM
Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4.

Frontiers in immunology

Panagioti E, Boon L, Arens R, van der Burg SH.
PMID: 28265272
Front Immunol. 2017 Feb 20;8:144. doi: 10.3389/fimmu.2017.00144. eCollection 2017.

There is an imperative need for effective preventive vaccines against human cytomegalovirus as it poses a significant threat to the immunologically immature, causing congenital disease, and to the immune compromised including transplant recipients. In this study, we examined the...

Cite
Panagioti E, Boon L, Arens R, et al. Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4. Front Immunol. 2017;8:144doi: 10.3389/fimmu.2017.00144.
Panagioti, E., Boon, L., Arens, R., & van der Burg, S. H. (2017). Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4. Frontiers in immunology, 8144. https://doi.org/10.3389/fimmu.2017.00144
Panagioti, Eleni, et al. "Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4." Frontiers in immunology vol. 8 (2017): 144. doi: https://doi.org/10.3389/fimmu.2017.00144
Panagioti E, Boon L, Arens R, van der Burg SH. Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4. Front Immunol. 2017 Feb 20;8:144. doi: 10.3389/fimmu.2017.00144. eCollection 2017. PMID: 28265272; PMCID: PMC5316540.
Copy Download .nbib Format: NLM
PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status.

Thrombosis research

Vignoli A, Tessarolo S, Marchetti M, Gamba S, Piras F, Finazzi G, van der Meijden PE, Swieringa F, Ten Cate H, Heemskerk JW, Rambaldi A, Falanga A.
PMID: 27161708
Thromb Res. 2016 Apr;140:S183. doi: 10.1016/S0049-3848(16)30152-9. Epub 2016 Apr 08.

INTRODUCTION: The myeloproliferative neoplasms ET and PV are characterized by a high incidence of both arterial and venous thrombosis, and/or microcirculatory disturbances. Three somatic mutations, i.e. JAK2-V617F, Calreticulin (CalR) and MPL, commonly found in these diseases, correlate with different...

Cite
Vignoli A, Tessarolo S, Marchetti M, et al. PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. Thromb Res. 2016;140:S183doi: 10.1016/S0049-3848(16)30152-9.
Vignoli, A., Tessarolo, S., Marchetti, M., Gamba, S., Piras, F., Finazzi, G., van der Meijden, P. E., Swieringa, F., Ten Cate, H., Heemskerk, J. W., Rambaldi, A., & Falanga, A. (2016). PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. Thrombosis research, 140S183. https://doi.org/10.1016/S0049-3848(16)30152-9
Vignoli, A, et al. "PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status." Thrombosis research vol. 140 (2016): S183. doi: https://doi.org/10.1016/S0049-3848(16)30152-9
Vignoli A, Tessarolo S, Marchetti M, Gamba S, Piras F, Finazzi G, van der Meijden PE, Swieringa F, Ten Cate H, Heemskerk JW, Rambaldi A, Falanga A. PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. Thromb Res. 2016 Apr;140:S183. doi: 10.1016/S0049-3848(16)30152-9. Epub 2016 Apr 08. PMID: 27161708.
Copy Download .nbib Format: NLM
Erratum to: The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases.

Journal of clinical immunology

Sonneveld ME, van der Schoot CE, Vidarsson G.
PMID: 27121694
J Clin Immunol. 2016 May;36:82. doi: 10.1007/s10875-016-0285-2.

No abstract available.

Cite
Sonneveld ME, van der Schoot CE, Vidarsson G. Erratum to: The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases. J Clin Immunol. 2016;36:82doi: 10.1007/s10875-016-0285-2.
Sonneveld, M. E., van der Schoot, C. E., & Vidarsson, G. (2016). Erratum to: The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases. Journal of clinical immunology, 3682. https://doi.org/10.1007/s10875-016-0285-2
Sonneveld, Myrthe E, et al. "Erratum to: The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases." Journal of clinical immunology vol. 36 (2016): 82. doi: https://doi.org/10.1007/s10875-016-0285-2
Sonneveld ME, van der Schoot CE, Vidarsson G. Erratum to: The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases. J Clin Immunol. 2016 May;36:82. doi: 10.1007/s10875-016-0285-2. PMID: 27121694.
Copy Download .nbib Format: NLM
Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients.

ERJ open research

Broekman W, Roelofs H, Zarcone MC, Taube C, Stolk J, Hiemstra PS.
PMID: 27730190
ERJ Open Res. 2016 Jun 28;2(2). doi: 10.1183/23120541.00045-2015. eCollection 2016 Apr.

Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD affects BM-MSCs. To investigate this, BM-MSCs from nine COPD patients and nine non-COPD age-matched...

Cite
Broekman W, Roelofs H, Zarcone MC, et al. Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients. ERJ Open Res. 2016;2(2)doi: 10.1183/23120541.00045-2015.
Broekman, W., Roelofs, H., Zarcone, M. C., Taube, C., Stolk, J., & Hiemstra, P. S. (2016). Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients. ERJ open research, 2(2), . https://doi.org/10.1183/23120541.00045-2015
Broekman, Winifred, et al. "Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients." ERJ open research vol. 2,2 (2016). doi: https://doi.org/10.1183/23120541.00045-2015
Broekman W, Roelofs H, Zarcone MC, Taube C, Stolk J, Hiemstra PS. Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients. ERJ Open Res. 2016 Jun 28;2(2). doi: 10.1183/23120541.00045-2015. eCollection 2016 Apr. PMID: 27730190; PMCID: PMC5005173.
Copy Download .nbib Format: NLM
Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report.

Hippokratia

Mihaylov G, Varbanova V, Stoeva V, Dikov T.
PMID: 29097894
Hippokratia. 2016 Jul-Sep;20(3):241-243.

BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological malignancy that originates in an abnormal pluripotent bone marrow stem cell. CML is consistently associated with the expression of the CASE REPORT: We report a case of a primary extranodal marginal...

Cite
Mihaylov G, Varbanova V, Stoeva V, et al. Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report. Hippokratia. 2016;20(3):241-243
Mihaylov, G., Varbanova, V., Stoeva, V., & Dikov, T. (2016). Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report. Hippokratia, 20(3), 241-243.
Mihaylov, G, et al. "Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report." Hippokratia vol. 20,3 (2016): 241-243.
Mihaylov G, Varbanova V, Stoeva V, Dikov T. Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report. Hippokratia. 2016 Jul-Sep;20(3):241-243. PMID: 29097894; PMCID: PMC5654445.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1323 entries